CELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Financial Statements and Exhibits
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit 99.1 – Press Release dated June 28, 2018

CELGENE CORP /DE/ Exhibit
EX-99.1 2 tv497569_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1         CELGENE AND ACCELERON ANNOUNCE luspatercept achieved primary and key secondary endpointS IN PHASE III ‘medalist’ study in Patients with low-to-Intermediate risk myelodysplastic syndromes   Results showed significant improvement in red blood cell transfusion independence compared to placebo   Safety profile generally consistent with previously published data   Regulatory submissions planned in the United States and Europe in the first half of 2019   SUMMIT,…
To view the full exhibit click here

About CELGENE CORPORATION (NASDAQ:CELG)

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.